期刊文献+

慢性乙型肝炎YMDD变异与中医证型的临床研究 被引量:5

Clinical Research on Chronic Hepatitis B YMDD Variance and TCM Types
下载PDF
导出
摘要 [目的]探讨拉米夫定治疗后慢性乙型肝炎HBV-YMDD变异与中医证型的相关性。[方法]可统计的100例服用拉米夫定的慢性乙型肝炎患者,根据中医辨证分为肝郁脾虚组40例,涅热中阻组20例,肝肾阴虚组20例,瘀血阻络组20例。分别检测肝功能、乙肝三系定量、HBV-DNA定量、YMDD变异。比较6、12、18个月时各组的ALT、AST、TBlL,HBeAg转阴率,HBeAg/HBeAb转换率,YMDD变异率。[结果]各组HBV-YMDD变异发生率6个月时无差异或差异无统计学意义。12、18个月时,瘀血阻络组最高,肝肾阴虚组次之,肝郁脾虚组和湿热中阻组最低,差异有统计学意义。[结论]拉米夫定治疗后慢性乙型肝炎HBV-YMDD变异发生率与中医证型之间有一定的相关性。 [Objective]To discuss the relativity between TCM types and chronic hepatitis B YMDD variance after treated with LAM.[Method]100 cases of said patients orally taking LAM,under TCM types,were divided into depressed liver and deficient spleen group 40 cases,damp-heat blocking the middle group 20 cases,Yin deficiency of liver and kidney group 20,blood stasis blocking collaterals group 20.Respectively test liver function,3-system ration B,HBV-DNA and YMDD variance of hepatitis. Compare the negative rates of ALT,AST,TBIL and HbeAg,the conversion rate of HBeAg/HbeAb,the variance rate of YMDD at 6,12,and 18 months.[Result]The HBV-YMDD variance rates at 6 months had no difference or were without statistical mean- ing in all groups;at 12 and 18 months,blood stasis blocking collaterals group was highest,then the deficiency of liver and kidney group,last the depressed liver and deficient spleen group and damp-heat blocking the middle group,with statistical meaning. [Conclusion]There's relativity between TCM types and chronic hepatitis B HBV-YMDD variance after treated with LAM.
作者 缪锡民 章亮
出处 《浙江中医药大学学报》 CAS 2007年第6期702-703,共2页 Journal of Zhejiang Chinese Medical University
关键词 慢性乙型肝炎 HBV-YMDD变异 拉米夫定 辨证分型 chronic hepatitis HBV-YMDD variance LAM differentiation types
  • 相关文献

参考文献6

二级参考文献13

  • 1Lok AS,McMahon BJ.Chronic hepatitis B[].Hepatology.2001
  • 2Maria Buti,Rafael Esteban.Entecavir, FTC, L-RMAU, LdT and others[].Journal of Hepatology.2003
  • 3Fontana RJ.Mangement of patients with decompensated HBV cirrhosis[].Seminars in Liver Disease.2003
  • 4Hom X,Little NR,Gardner SD,et al.Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection[].Pediatric Infectious Disease.2004
  • 5Kobayashi S,Ide T,Sata M,et al.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers[].Journal of Hepatology.2001
  • 6Li LL,Chun TW,Yin ML,et al.Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy[].Hepatology.2000
  • 7Liaw YF,Sung JJY,Chow WC,et al.Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial[].Hepatology.2003
  • 8Liaw YF,Leung N,Guan R,et al.Asian-pacific consensus statement on the management of chronic hepatitis B:[].An updateJ Gastroenterol Hepatol.2003
  • 9Jonas MM,Kelley DA,Mizerski J,et al.Clinic trial of lamivudine in children with chronic hepatitis B[].The New England Journal of Medicine.2002
  • 10Sokal EM.Drug treatment of pediatric chronic hepatitis B[].Paediatric Drugs.2002

共引文献607

同被引文献102

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部